The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory.
The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory.
复制标题
DOI：
10.1016/j.bbr.2016.11.042
复制
发表时间：
2017-03-01
影响因子：
2.7
通讯作者：
Crystal JD
中科院分区：
文献类型：
--
作者：
Smith AE;Slivicki RA;Hohmann AG;Crystal JD
化疗药物被广泛用于治疗系统性癌症患者。这些疗法的疗效受到其不良副作用的影响，例如认知缺陷对癌症幸存者的生活质量产生负面影响。认知副作用发生在多个领域，包括记忆、执行功能和处理速度。这种损害在认知挑战下会加剧，一部分患者会经历长期的损害。大鼠的情节记忆可以用来源记忆任务来检验。在目前的研究中，大鼠接受了紫杉醇(一种紫杉烷衍生的化疗药物)，并使用来源记忆任务检查了学习和记忆功能。紫杉醇治疗不会损害空间和情景记忆，紫杉醇治疗的大鼠并不更容易受到认知挑战的影响。在记忆没有受损的情况下，紫杉醇治疗损害了对新规则的学习，证明了对实验意外情况变化的敏感性降低。这些发现为癌症化疗引起的认知障碍的性质提供了新的信息，特别是关于紫杉醇治疗后情景记忆和新学习的不协调脆弱性。
Chemotherapeutic agents are widely used to treat patients with systemic cancer. The efficacy of these therapies is undermined by their adverse side-effect profiles such as cognitive deficits that have a negative impact on the quality of life of cancer survivors. Cognitive side effects occur across a variety of domains, including memory, executive function, and processing speed. Such impairments are exacerbated under cognitive challenges and a subgroup of patients experience long-term impairments. Episodic memory in rats can be examined using a source memory task. In the current study, rats received paclitaxel, a taxane-derived chemotherapeutic agent, and learning and memory functioning was examined using the source memory task. Treatment with paclitaxel did not impair spatial and episodic memory, and paclitaxel treated rats were not more susceptible to cognitive challenges. Under conditions in which memory was not impaired, paclitaxel treatment impaired learning of new rules, documenting a decreased sensitivity to changes in experimental contingencies. These findings provide new information on the nature of cancer chemotherapy-induced cognitive impairments, particularly regarding the incongruent vulnerability of episodic memory and new learning following treatment with paclitaxel.